GlassScriptPhysician profile
Judy P Rawls
NPI 1598748931
$12,032.84
in general payments reported to CMS, 2019-2025
44 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $1,654 · 2021: $2,637 · 2022: $1,877 · 2023: $1,669 · 2024: $1,527 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,443.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,349.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,411.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,297.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,184.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $853.98 | 2019-2025 | |
| Amgen INC. | $564.17 | 2019-2025 | Otezla, Repatha, Otezla |
| Amarin Pharma, INC. | $425.56 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $395.39 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $390.10 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Allergan, INC. | $368.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $357.22 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $262.82 | 2022-2025 | |
| Eisai INC. | $240.12 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $231.53 | 2022 | |
| Currax Pharmaceuticals LLC | $175.64 | 2021-2025 | Contrave |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Rawls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.